Large clinical outcome trials have validated that SGLT2 inhibitors (Empagliflozin or Canagliflozin) improve renal outcomes, as defined by reducing the risk of deteriorated nephropathy, progression to macroalbuminuria, incidence of renal replacement therapies, and occurrence of doubling of serum creatinine in patients with T2DM (Wanner et al., 2016; Neal et al., 2017). Here, SLC5A2 is linked to kidney disorder.